Can you get medical cannabis for complex regional pain syndrome in the UK?

Complex regional pain syndrome is rare, severe, and badly served by the treatments available. Pain is out of proportion to the original injury, and the standard options — physiotherapy, neuropathic pain medicines, nerve blocks — often fall short. That is the setting in which UK specialists consider a cannabis-based medicine, on the thinnest evidence base on this site.

The short answer

  • CRPS is assessed case by case by UK private specialists, usually late in the treatment pathway.
  • There is no licensed cannabis-based medicine for CRPS anywhere in the UK.
  • The published evidence is a small UK case series — no randomised controlled trial exists.
  • Rehabilitation remains central. Pain relief that does not support movement rarely helps CRPS.
  • Multidisciplinary pain care is the recommended UK approach, and should continue alongside anything else.

Is complex regional pain syndrome treated with medical cannabis in the UK?

It is considered, individually, and almost always in people who have already been through specialist pain services without adequate relief. It is not an NHS treatment for CRPS and no product is licensed for it.

CRPS usually follows an injury or surgery and produces burning pain, swelling, changes in skin colour and temperature, sensitivity to light touch, and loss of function in the affected limb. UK practice, set out in Royal College of Physicians guidance, is built around early multidisciplinary care: physical rehabilitation, pain management, and psychological support together, with medicines playing a supporting role rather than a leading one.

A specialist considering a cannabis-based medicine for CRPS is looking for something that makes rehabilitation possible — not something that replaces it. If pain relief comes at the cost of engagement with physiotherapy, it has not helped.

What the evidence actually shows

This is the weakest evidence base on this site. There is no randomised controlled trial of cannabis-based medicines in complex regional pain syndrome. What exists is a small UK case series and indirect evidence borrowed from the neuropathic pain literature.

Researchers analysing the UK Medical Cannabis Registry published a clinical outcomes analysis for CRPS patients, tracking patient-reported pain, sleep, anxiety and quality-of-life measures over six months. It reported improvements across those measures with adverse events that were mostly mild or moderate. As a case series with no control group, it cannot distinguish the medicine from the natural course of the condition, from regression to the mean in people who enrolled at their worst, or from the effect of expectation. The authors say as much.

Anyone telling you the evidence for CRPS is strong is not describing the literature.

The study behind that paragraph

UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Complex Regional Pain Syndrome. Brain and Behavior. 2025;15(9). A case series assessing changes in patient-reported outcome measures over six months in CRPS patients on the UK registry. No control group, so no causal conclusion can be drawn.

Read the paper →

What a specialist will want to see

There is no UK list of qualifying conditions, so nothing here entitles you to a prescription. A specialist works through your history and decides whether a monitored trial is justified for you. For complex regional pain syndrome they will typically look at:

The general requirements — age, a documented diagnosis, the convention that two standard treatments have been tried, and access to your medical records — are covered in What are the requirements?

Risks and reasons a specialist may say no

With evidence this thin, the main risk is a mismatch between hope and outcome. CRPS is a condition where people have often been let down repeatedly, and a specialist who promises a result rather than a trial is not being straight with you.

The pharmacological risks are the usual ones: drowsiness, dizziness, impaired concentration, dry mouth and driving impairment from THC-containing products. Sedation matters more than usual here, because anything that reduces your capacity for physical rehabilitation works against the treatment that has the best evidence behind it. Personal or family history of psychosis, unstable mental illness, pregnancy and breastfeeding all count against treatment.

If you want to take this further

The useful next step is a proper assessment, not a better list. Gather your diagnosis, the treatments you have already tried and what happened with each, and your current medicines — that is what a specialist needs in order to give you a straight answer.

The consultation itself, and what happens after it, is set out in What is the process to get a medical cannabis prescription? If complex regional pain syndrome is not the only thing you are being treated for, say so early: other conditions and other medicines change the assessment.

Frequently asked questions

Can I get medical cannabis for CRPS in the UK?

It is considered case by case by private specialists, usually after specialist pain services have not given adequate relief. There is no licensed cannabis-based medicine for CRPS and no NHS route for it.

Is there evidence that cannabis helps CRPS?

There is no randomised controlled trial. The published UK evidence is a small case series from the UK Medical Cannabis Registry reporting improvements in pain, sleep and quality of life over six months, which cannot separate the medicine from the natural course of the condition.

Should I stop physiotherapy if I start a cannabis-based medicine?

No. Physical rehabilitation within a multidisciplinary pain service is the approach with the strongest support in UK guidance for CRPS. Medicines are there to support that, and a treatment that leaves you too sedated to rehabilitate is working against you.

Why is the evidence so limited for CRPS?

CRPS is rare, which makes randomised trials hard to recruit for, and outcome measurement is difficult because the condition fluctuates. That is a reason for caution about all treatments in CRPS, not a reason to assume any particular one works.

Sources and further reading

Every factual statement on this page is drawn from the following public sources. Links open in a new tab and are not affiliated with Flora House.

  1. Erridge S, et al. UK Medical Cannabis Registry: a clinical outcomes analysis for complex regional pain syndrome. Brain and Behavior (2025)
  2. Royal College of Physicians: Complex regional pain syndrome in adults (2nd edition) — UK guidelines for diagnosis, referral and management
  3. NHS: Complex regional pain syndrome
  4. NICE guideline NG144: Cannabis-based medicinal products
  5. NHS: Medical cannabis (and cannabis oils)
  6. House of Commons Library briefing CBP-8355: Medical use of cannabis
  7. MHRA: The supply, manufacture, importation and distribution of unlicensed cannabis-based products for medicinal use

Patient guide · Written by the Flora House editorial team · Last reviewed: 31 August 2026